Interferon alfa-2b is a Recombinant Protein owned by Lee’s Pharmaceutical Holdings, and is involved in 4 clinical trials, which were completed.

Interferon alpha-2b is an immunomodulatory agent innates immune system response to viral pathogens by acting upon external cellular receptors and stimulating a host of intracellular and extracellular activities. In infected cell interferon alpha-2b action is thought to stimulate the induction of enzymes such as 2'5' oligoadenylate synthetase and protein kinase R (PKR), which function to cause degradation of viral RNA and inhibit protein synthesis to antagonize viral propagation. Extracellularly interferon alpha-2b is thought to also enhance the expression of human leukocyte antigens (HLAs) and other HPV-specific antigens on the cell surface, thereby promoting recognition of the infected cells by cytotoxic T cells, natural killer cells and other cells of the innate immune response.

The revenue for Interferon alfa-2b is expected to reach a total of $692m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Interferon alfa-2b NPV Report.

Interferon alfa-2b is currently owned by Lee’s Pharmaceutical Holdings.

Interferon alfa-2b Overview

Interferon alpha-2b (Yallaferon) is an antiviral preparation. It is formulated as gel for topical application. Yallaferon is indicated for the treatment of genital warts, genital herpes, labial herpes and Herpes Zoster and cervicitis.

Lee’s Pharmaceutical Holdings Overview

Lee’s Pharmaceutical Holdings (Lee’s Pharmaceutical) is a health care provider. The company focuses on the development, manufacturing and marketing of novel therapies and contract research services. It provides products in the therapy areas of urology, cardiovascular oncology, pediatrics, dermatology, woman health, hematology, ophthalmology, dermatology, and obstetrics. The company’s products include bredinin tablets, dicoflor powder, episil oral gel, ferplex oral solution, rasilez tablets, teglutik oral suspension, cetraxal plus ear drops, intrarosa pessaries, lutrate depot, adasuve inhalation powder, teglutik oral suspension, natulan capsules, carnitene injection, readyfusor infusion pump, unidrox tablets, zanidip tablets, zingo needleless injection, among others. It also offers products in the form of gel, injection, tablets, oral solutions and infusion systems. Its products are marketed in the regions of Hong Kong, China and Taiwan. The company works in partnership with other organizations for the development and distribution rights for products across the US, Japan and other regions in Europe. It operates through its manufacturing facility located at Hefei City, China. Lee’s Pharmaceutical is headquartered in Hong Kong.

The company reported revenues of (Hong Kong Dollars) HKD1,266.2 million for the fiscal year ended December 2021 (FY2021), an increase of 4.1% over FY2020. The operating profit of the company was HKD1,978.6 million in FY2021, compared to an operating profit of HKD151.9 million in FY2020. The net profit of the company was HKD1,987.2 million in FY2021, compared to a net profit of HKD129.3 million in FY2020. The company reported revenues of HKD387 million for the third quarter ended September 2022, an increase of 19.3% over the previous quarter.

Quick View – Interferon alfa-2b

Report Segments
  • Innovator (NME)
Drug Name
  • Interferon alfa-2b
Administration Pathway
  • Topical
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.